Fusitrim is commonly used to help with bacterial skin infections that also involve symptoms related to inflammatory or irritative states, such as swelling, redness, and itching.

The combination of fusidic acid and hydrocortisone is used to manage skin conditions like atopic dermatitis (eczema) where the skin is red, swollen, itchy, and secondarily infected by bacteria.

It is applied in situations involving recurrent or episodic manifestations, such as skin conditions like eczema or dermatitis that have developed a secondary infection, or for infected cuts or sores. This assists with managing the bacterial presence and helps ease the discomfort associated with inflammation.

“It is applied across domains where additional symptomatic support is needed to help ease discomfort and contribute to functional stability.”

A key therapeutic benefit is applied in addressing the symptom cluster of both infection and inflammation. This supports the patient during difficult episodes by easing distress and assists with maintaining functional stability when symptoms interfere with routine activities.

---

Quick Fact: Relief for Dual Symptoms The therapeutic action is relevant for managing skin conditions where both a bacterial infection and bothersome inflammation are present.

Regulatory References

1. Details for: FUCIDIN H - Drug and Health Product Register

The eligibility for using Fusitrim is strictly defined by regulatory documents, focusing on populations for whom the medicine is absolutely contraindicated or requires conditional use due to the corticosteroid component, Hydrocortisone.

Population Status	Regulatory Rule
Allowed Use	Adults with dermatitis (e.g., atopic or contact) complicated by a fusidic acid-sensitive bacterial infection.
Absolute Contraindications	Must not be used by patients with hypersensitivity to the active ingredients or excipients. The medicine is contraindicated in untreated primary fungal, viral, or bacterial skin infections, rosacea, perioral dermatitis, and skin manifestations of tuberculosis or syphilis.
Age-Related Limitations	Use is not established in children under 3 years of age. The medicine must be used with care in all children due to their increased susceptibility to systemic effects from topical corticosteroids. Older adults have no specific restrictions documented.
Conditional Use	Pregnancy: Can be used if clinically needed, but avoid extensive or prolonged use. Lactation: Can be used, but application must be avoided on the breast to prevent infant exposure. Use is also restricted near the eyes.

This eligibility profile establishes who is eligible and who is excluded or restricted from using the medicine based on official, label-based criteria published by regulatory authorities.

Interactions with other medicines and products

The interaction profile for Fusitrim, a topical combination of Fusidic Acid and Hydrocortisone, is structurally defined by the minimal systemic absorption risk associated with its administration route. Official regulatory documents indicate that no formal drug-drug interaction studies have been performed for this topical product, and interactions with systemically administered medicinal products are formally considered minimal.

---

Official Interaction Statements

The most significant interaction-related caution pertains to exposure modification. The product label acknowledges that application over large surface areas, use for prolonged periods, or application under occlusive dressings may increase the systemic absorption of the hydrocortisone component. This increased absorption can potentially lead to systemic corticosteroid effects, such as the suppression of the hypothalamic-pituitary-adrenal (HPA) axis.

Classification	Regulatory Status
Specific Interacting Medicines	None explicitly documented as interacting with the topical formulation.
Food, Alcohol, Herbal Products	No interactions with food, alcohol, or herbal products are documented in regulatory sources for the topical formulation.

This absorption-related exposure risk is noted to be greater in paediatric patients due to their higher body surface area-to-weight ratio. No mandatory timing or separation requirements are listed for co-administration with other medicinal products in the regulatory documentation.

How Fusitrim Works: Pharmacodynamic Mechanism

Fusitrim acts via the coordinated action of its two active components, engaging two distinct mechanistic domains to modulate defined biological pathways. The Fusidic Acid component targets the bacterial enzyme Elongation Factor G (EF-G), a protein essential for the synthesis of new microbial proteins. By irreversibly binding to and inhibiting EF-G, this mechanism effectively arrests the process of protein synthesis, leading to suppression of bacterial proliferation (bacteriostasis).

Simultaneously, Hydrocortisone acts as an agonist for the Cytoplasmic Glucocorticoid Receptor (GR) in skin cells. This binding initiates a cellular cascade that translocates the receptor complex into the nucleus, where it modulates gene expression. This mechanism results in the suppression of genes that produce pro-inflammatory mediators (like cytokines) and the activation of anti-inflammatory genes, resulting in decreased vascular permeability and localized vasoconstriction. This dual-action pathway modulates the activity of key cellular mechanisms, resulting in defined alterations in protein synthesis and gene transcription.

How to Use Fusitrim (Fusidic Acid/Hydrocortisone)

Fusitrim is a fixed-dose combination product containing the antibacterial agent Fusidic Acid and the mild corticosteroid Hydrocortisone, and its application follows clinical guidelines. These instructions define the proper method, frequency, and duration of use.

---

Official Administration Protocol

The medicine is designed for topical use (cutaneous application) only. The administration parameters for the cream/ointment formulation (2% Fusidic Acid/1% Hydrocortisone Acetate) are summarized below:

Administration Parameter	General Instruction
Route and Quantity	Applied directly to the skin as a small quantity (a thin smear) and gently massaged into the affected area.
Dosing Frequency	Apply the preparation two to three times daily to the area being treated.
Maximum Duration	The course of treatment must not normally exceed 14 days (two weeks).

---

Application Constraints and Age-Specific Rules

Adherence to the correct procedure is essential. Patients are explicitly instructed to avoid applying the product in or near the eye. If an occlusive dressing is used, the frequency of application may need to be reduced. Regarding the paediatric population, use in children under 3 years of age is generally not recommended or requires specific clinical caution.

Research evidence / Overview of studies for Fusitrim

Evidence for Inflammatory Skin Conditions Complicated by Infection

Research exploring the combination of fusidic acid and hydrocortisone primarily involves Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews. These studies were observed in conditions like eczema or dermatitis when they are also experiencing a suspected bacterial infection.

Researchers explored the medicine by setting up trials that compared the combination cream against a cream containing only the steroid component (hydrocortisone) or a non-active cream. The primary outcomes related to symptom severity that studies monitored included measurements of disease severity, such as changes in the degree of redness, swelling, and itching observed over a typical short treatment period of seven to fourteen days. Additionally, research monitored bacteriological outcomes, focusing on how patterns of target bacteria, such as Staphylococcus aureus, evolved in the observed populations.

Findings describe patterns observed in the studies that contribute to understanding short-term changes in symptoms. However, when comparing the combination product to the steroid component alone for the treatment of mild to moderate infected eczema, the evidence is limited and findings were mixed regarding the measurement of additional clinical outcomes when including the antibiotic. Research highlights measurements taken during the study period, and the difference between the combination product and the single agent for outcomes reflecting clinical status was not consistently described across all trials.

---

Research on Localized Superficial Skin and Soft-Tissue Infections

Research examining the anti-infective action of this medicine relies heavily on studies of the fusidic acid component itself. Studies explored its use in treating localized superficial skin and soft-tissue infections (SSTI), which are acute or disruptive episodes caused by common skin bacteria.

The types of research conducted were mainly Comparative Trials and RCTs that were studied for short-term symptom changes. These trials monitored outcomes related to the time it took for lesions to resolve and the proportion of patients who met the study's primary clinical endpoint. Research examined the anti-bacterial component's effect in targeting key pathogens under specific trial conditions. Data describe patterns related to how the anti-infective component was evaluated against certain bacteria, which contributes to the broader evidence landscape for the combination product.

---

Long-Term Studies and Follow-up in the Research Record

The available clinical research for the combination product primarily focuses on short-term changes, as trials typically observe responses over defined time intervals, usually 7 to 14 days, reflecting the short duration of acute treatment. Some follow-up periods were extended to a few weeks or months to monitor for recurrence.

However, evidence is limited for long-term outcomes. Research highlights what is known—and what is still uncertain—about patterns of recurrence. Specifically, data are still emerging, and long-term effects are not fully established regarding recurrence rates of the underlying condition after treatment is completed. The short follow-up durations were limited in providing comprehensive insight into the long-term status of conditions characterized by fluctuating or episodic manifestations.

---

Evidence in Specific Patient Groups (Special Populations)

The research record includes studies where the medicine was evaluated in a range of patient groups, including children with infected inflammatory skin conditions. Studies explored populations including infants as young as three months old, reflecting that the medicine was studied for use across various pediatric ages.

Findings are drawn only from the populations studied. Data for certain groups remain insufficient, and research has less information available for specific patient subsets, such as a large number of older adults or those with complex, pre-existing comorbid conditions.

---

What Is Still Uncertain About Fusitrim

The current evidence contributes to understanding symptom patterns, but it also reveals specific research gaps. The main limitation is that the evidence quality varies across studies, and findings were mixed, particularly regarding the measured difference between the combination product and the steroid alone for all cases of mild to moderate infected eczema.

Furthermore, there is limited information for long-term outcomes, as the follow-up durations were limited. This means research provides context but does not determine whether an individual will respond similarly regarding long-term recurrence or the long-term status of the skin condition. The research is ongoing to help contextualize how patients reported their experience and to provide further insight into the balance of treatments.

Key Studies & References Details for: FUCIDIN H - Canadian Drug and Health Product Register

Common questions about Fusitrim (FAQ)

---

Q: What should I do if I forget a dose of the cream?

If a dose is missed, regulatory documents suggest applying it as soon as it is remembered. However, if it is nearly time for the next scheduled application, it is generally advised to skip the missed dose and continue with the regular schedule. Official product information states that double doses should not be used to make up for a missed application.

---

Q: How quickly does Fusitrim start to work for my skin condition?

According to product information and clinical observations, improvement in skin condition is commonly observed after a few days of starting treatment. This timeframe reflects the typical short-term response monitored in studies for acute inflammatory conditions.

---

Q: What are the symptoms of an allergic reaction to Fusitrim (hypersensitivity)?

Signs of a serious allergic reaction, or hypersensitivity, may include swelling of the face, lips, mouth, or tongue, and difficulty breathing. The skin may also develop a severe, generalized rash or hives (itchy, raised areas of skin). Experiencing any of these symptoms warrants seeking immediate medical attention or advice.

---

Q: Is it safe to use Fusitrim while pregnant or breastfeeding?

Official product information states that Fusitrim can be used during pregnancy if a doctor considers it clinically necessary, but extensive or prolonged use is advised against. When breastfeeding, application to the breast area is advised against to prevent infant exposure, and hand hygiene is recommended before handling the infant.

---

Q: What brand names is the combination of Fusidic Acid and Hydrocortisone sold under?

The combination of the antibiotic Fusidic Acid and the corticosteroid Hydrocortisone is marketed under various trade names globally. While this drug is referred to as Fusitrim, other common trade names may include Fucidin H and Fucizon, depending on the country and manufacturer.

---

Q: How should I apply Fusitrim if I am also using another topical product on the same area?

To ensure Fusitrim's efficacy and absorption, regulatory guidance often recommends separating its application from other topical products, such as moisturizers. It is generally advised to wait a specific period, often around 30 minutes, between applying this cream and any other topical products to the same area.

---

Q: What should I do if I accidentally swallow some of the Fusitrim cream?

Fusitrim is strictly for topical use (on the skin). If an excessive or accidental amount is swallowed, seeking immediate medical advice is necessary. This may involve contacting a doctor, hospital emergency department, or a local Poison Control Center.

---

Q: Is it safe to use Fusitrim on open wounds or broken skin?

Product information generally advises against applying the cream to damaged or irritated skin, such as open wounds or severe cuts. Use on such areas requires specific direction from a healthcare professional to assess the risks and benefits.

---

Q: How do I properly clean my hands after applying the cream?

Thorough hand washing is an integral part of the application procedure, unless the hands are the area being treated. This practice helps prevent the accidental transfer of the medication to other sensitive areas, such such as the eyes, or to other individuals.

---

The storage and disposal instructions for Fusitrim, a topical preparation, are strictly governed by regulatory requirements to ensure product integrity and public safety.

Official Storage Conditions

Fusitrim must be stored below 30 C and must not be refrigerated, as per official labeling. The container should be kept tightly closed to protect the medicine from environmental exposure. To prevent accidental ingestion or misuse, the product must always be kept out of the sight and reach of children and pets.

Stability and Disposal Rules

Once the tube is first opened, any unused portion of the medicine must be discarded after 3 months. For disposal, the medicine must not be thrown away via wastewater or household waste. All unused or expired product must be disposed of in accordance with local pharmaceutical waste requirements.